德纳维制药

DVAX NASDAQ
3.660
0.000
0.00%
盘后: 3.660 0 0.00% 17:04 07/19 EDT
开盘
3.660
昨收
3.660
最高
3.700
最低
3.560
成交量
57.39万
成交均量(3M)
137.09万
52周最高
16.15
52周最低
3.400
换手率
0.88%
市值
2.38亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供德纳维制药 DVAX股票价格,德纳维制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
展开 >

最近浏览

名称
价格
涨跌幅